Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Program Established to Foster Vibrant Bioscience Cluster in the Region
On Friday, November 18th at the Long Island High Technology Incubator, the Long Island BioMentor Initiative (LIBMI) will be hosting its first full-day mentor training session for the founding mentors of the new initiative. Led by the Center for Biotechnology at Stony Brook University and Accelerate Long Island, the LIBMI has been established on behalf of the Long Island Bioscience Hub – an NIH-designated Research, Evaluation, and Commercialization Hub. The LIBMI is a platform to bring highly qualified, volunteer mentors together with motivated, early-stage bioentrepreneurs to provide guidance and support as they advance their business strategy.
The LIBMI is based on the successful mentoring model developed at the Massachusetts Institute of Technology’s (MIT) Venture Mentoring Service (VMS), and created in collaboration with Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, Hofstra University, and the Feinstein Institute at Northwell Health Systems. Through MIT VMS’s team mentoring approach, the LIBMI aims to provide objective and unbiased advice that will help entrepreneurs navigate the challenging landscape that growing bioscience ventures face. Mentors participating in the November 18th training session led by a MIT VMS Co-Director will benefit from curriculum and interactive teachings along with a mentoring session with one of the first entrepreneurs chosen to serve as mentee.
“There is an abundance of innovation on Long Island as well as a growing pool of entrepreneurs looking to create ventures that will take root and grow in the region” said Mark Lesko, Board Member, Accelerate Long Island. Diane Fabel, Director of Operations for the Center for Biotechnology added “Establishing a formal mentoring program, specifically for the bioscience sector, is critical as these companies need diverse support in order for them to thrive.”
The initiative employs the team mentoring approach and brings together experts with great depth and a range of experiences. The members of the founding mentor team include Dr. Linda Amper, Chief People Officer of Clever Devices; Dr. Gian Luca Araldi, founder and principal of US Pharma Services; Kara Cannon, Global Head of Sales & Marketing of Enzo Life Sciences, Inc.; Dr. Anil Dhundale, former Executive Director of the Long Island High Technology Incubator; Dr. Wayne Koff, President and CEO of Human Vaccines Project; Ric Overton, President of Overton Operations Advisors; Jeff Peacock, VP Global Quality Assurance and Regulatory Affairs at Henry Schein, Inc.; Dr. Saied Tousi, Managing Director for NW Advisors; and Edward Travaglianti, Market President of Long Island for TD Bank.
The entire process is guided by a statement of principles to ensure confidentiality and a conflict free environment. The initiative will build upon a suite of services and resources provided by the NIH-designated Research, Evaluation, and Commercialization Hub (LI Bioscience Hub), Accelerate Long Island and the Emerging Technology Fund, the New York State Center for Advanced Technology in Medical Biotechnology.
“It’s important to me to help support the entrepreneurial ecosystem on Long Island” founding mentor Ed Travaglianti stated, “and the team approach expands our capacity, allowing us to mentor more than one entrepreneur.”
Learn more about the Long Island BioMentor Initiative here.
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
The I-Corps™ at NIH Program helps current Phase I SBIR/STTR awardees from the NIH and CDC transition from researcher to entrepreneur.
This 8.5-week training program provides practical guidance from experienced industry professionals that will move you forward on your path toward commercialization. Past participants have written strong SBIR/STTR Phase II applications, won partnerships and investments, and built vast networks in the field.
Apply for the first cohort of FY2023 through the NIH ASSIST platform by 5:00 p.m. your local time on Wednesday, November 16.
Questions? Review the FAQs or contact us if you need help at icorps@mail.nih.gov.
[post_title] => NIH iCorps: Apply by Nov. 16
[post_excerpt] => Apply by 11/16 to joing the I-Corps™ at NIH Program helping current Phase I SBIR/STTR awardees from the NIH and CDC transition from researcher to entrepreneur.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-icorps-apply-by-nov-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 17:01:52
[post_modified_gmt] => 2022-12-13 17:01:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3954
[menu_order] => 13
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2824
[post_author] => 4
[post_date] => 2017-09-20 13:41:33
[post_date_gmt] => 2017-09-20 13:41:33
[post_content] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by Center for Biotechnology BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule treatment for Alzheimer’s disease (AD) over the next 3 years.
The award will enable the preparation and testing of Avanti’s proprietary compounds derivatized from natural catechins, which inhibit DYRK1A, an enzyme that modulates tau phosphorylation. Working with NY Institute for Basic Research and the University of California San Diego (UCSD), the company hopes to attenuate and potentially reverse pathogenesis for Alzheimer’s disease and other neurodegenerative diseases.
“This award marks a significant milestone for Avanti Biosciences and an important step for their research into a treatment for Alzheimer’s disease” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is thrilled to see another success for one of the emerging bioscience companies fueling our regional bioecosystem and we proudly support Dr. Araldi’s work as one of our BioEntrepreneurs-in-Residence.”
Dr. Gian Luca Araldi, Founder and Chief Executive Officer of Avanti, stated, “We are delighted to have been granted this funding from the NIA as it underscores the great need for innovative, effective treatments for this disease, and recognizes the potential benefits that our compounds may provide for patients with AD. The continuous support of Center for Biotechnology and the BioEntrepreneur-in-Residence program has been critical force in the development of our technology and the company as whole.”
More than five million people in the United States are living with Alzheimer’s disease, a progressive, irreversible, neurodegenerative disease that destroys memory and other cognitive abilities. It is the sixth leading cause of death in the United States and as the aging population in the country grows, the incidence rate is expected to rise dramatically.
Learn more about Avanti Biosciences: avantibiosciences.com
[post_title] => CFB BEIR Receives $1.9M SBIR Fast-Track
[post_excerpt] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by CFB BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule Alzheimer’s disease (AD) over the next 3 years.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-beir-receives-1-9m-sbir-fast-track
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:39:07
[post_modified_gmt] => 2018-01-23 14:39:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2824
[menu_order] => 138
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4534
[post_author] => 4
[post_date] => 2024-04-08 13:47:00
[post_date_gmt] => 2024-04-08 17:47:00
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
